The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 1, 2009, Pages 18-27

  Imbert Bismut, Françoise ^a   Naveau, Sylvie ^c   Morra, Rachel ^a   Munteanu, Mona ^b   Ratziu, Vlad ^a   Abella, Annie ^c   Messous, Djamila ^a   Thabut, Dominique ^a   Benhamou, Yves ^a   Poynard, Thierry ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Department of Biopredictive ^*  (France)

^c HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

Biomarkers; FibroMax; FibroTest; SteatoTest

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBOHYDRATE DEFICIENT TRANSFERRIN; GAMMA GLUTAMYLTRANSFERASE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FATTY LIVER; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ALCOHOLISM; BIOLOGICAL MARKERS; COHORT STUDIES; FATTY LIVER, ALCOHOLIC; FEMALE; HUMANS; LIVER CIRRHOSIS, ALCOHOLIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TRANSFERRIN;

EID: 58149218313     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32830a4f4c     Document Type: Article

References (26)

1. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45:846-854.
2. Anttila P, Järvi K, Latvala J, Romppanen J, Punnonen K, Niemelä O. Biomarkers of alcohol consumption in patients classified according to the degree of liver disease severity. Scand J Clin Lab Invest 2005; 65:141-151.
3. Heinemann A, Sterneck M, Kuhlencordt R, Rogiers X, Schulz KH, Queen B, et al. Carbohydrate-deficient transferrin: diagnostic efficiency among patients with end-stage liver disease before and after liver transplantation. Alcohol Clin Exp Res 1998; 22:1806-1812.
4. Nalpas B, Hispard E, Thepot V, Pot S, Dally S, Berthelot P. A comparative study between carbohydrate-deficient transferrin and gamma-glutamyl transpeptidase in a liver unit. J Hepatol 1997; 27:1003-1008.
5. Nyblom H, Berggren U, Balldin J, Olsson R. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol Alcohol 2004; 39:336-339.
6. Perret R, Froehlich F, Lavanchy D, Henry H, Bachman C, Pécoud A, et al. Is carbohydrate-deficient transferrin a specific marker for alcohol abuse? A study in patients with chronic viral hepatitis. Alcohol Clin Exp Res 1997; 21:1337-1342.
7. Hietala H, Koivisto P, Anttila P, Niemela O. Comparison of the combined marker GGT-CDT and the conventional laboratory markers of alcohol abuse in heavy drinkers, moderate drinkers and abstainers. Alcohol Alcohol 2006; 41:528-533.
8. Hock B, Schwarz M, Domke I, Grunert VP, Wuertemberger M, Schiemann U, et al. Validity of carbohydrate-deficient transferrin (%CDT), gamma-glutamyltransferase (gamma-GT) and mean corpuscular erythrocyte volume (MCV) as biomarkers for chronic alcohol abuse: a study in patients with alcohol dependence and liver disorders of non-alcoholic and alcoholic origin. Addiction 2005; 100:1477-1486.
9. Bell H, Tallaksen C, Sjåheim T, Weberg R, Raknerud N, Orjasaeter H, et al. Serum carbohydrate-deficient transferrin as a marker of alcohol consumption in patients with chronic liver diseases. Alcohol Clin Exp Res 1993; 17:246-252.
10. Bell H, Tallaksen CM, Try K, Haug E. Carbohydrate-deficient transferrin and other markers of high alcohol consumption: a study of 502 patients admitted consecutively to a medical department. Alcohol Clin Exp Res 1994; 18:1103-1108.
11. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357:1069-1075.
12. Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003; 39:222-230.
13. Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005; 3: 167-174.
14. Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, et al. The LIDO Study Group and the CYTOL Study Group. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterology 2006; 6:6.
15. Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, et al. Meta-analyses of Fibrotest diagnostic value in chronic liver disease BMC. Gastroenterology 2007; 7:40.
16. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005; 4:10.
17. Imbert-Bismut F, Messous D, Thibaut V, Myers RB, Piton A, Thabut D, et al. Intralaboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med 2004; 42:323-333.
18. Bedossa P, Poynard T, Naveau S, Martin ED, Agostini H, Chaput JC. Observer variation in assessment of liver biopsies of alcoholic patients. Alcohol Clin Exp Res 1988; 12:173-178.
19. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38:257-265.
20. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44:837-845.
21. Zhou X, Obuchowski N, McClish D. Statistical methods in diagnostic medicine. 1st ed. New York NY:John Wiley & Sons;2002.
22. Hintze JL. NCSS 2003 User Guide. Number Cruncher Statistical Systems 2003 software NCSS. Kaysville, Utah:NCSS.
23. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, et al.; LIDO Study Group. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135:100-110.
24. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38:1449-1457.
25. Biopredictive. Available at http://www.biopredictive.com. Accessed February 1, 2008.
26. Arndt T. Carbohydrate-deficient transferrin as a marker of chronic alcohol abuse: a critical review of preanalysis, analysis, and interpretation. Clin Chem 2001; 47:13-27.